Steady improvement seen in data from open-label extension study Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop… Read More »
Losmapimod continues to show promise
Epic Bio takes aim at DUX4
Updated 12-12-24 to reflect the chance in name from Epic Bio to Epicrispr Biotechnologies. Leading-edge CRISPR biotech chooses FSHD as its first disease target Epicrispr Biotechnologies, based in the San… Read More »
Corinne Bronfman, October 28, 1947 – October 7, 2022
She leaves a legacy of remarkable progress toward treatments for FSHD The FSHD Society was deeply saddened to learn of the passing of Corinne Bronfman on October7, in Washington DC…. Read More »
Roche announces Phase 2 trial in FSHD
The drug, GYM329, aims to boost muscle growth Roche, the Swiss pharmaceutical giant, has announced that it is launching an international Phase 2 clinical trial for facioscapulohumeral muscular dystrophy (FSHD)…. Read More »
Sanofi and miRecule to partner on FSHD drug program
Bringing two technologies together for a best-in-class therapy miRecule, Inc., a biotech based in Gaithersburg, Maryland, today announced a strategic collaboration and exclusive license agreement with pharmaceutical giant Sanofi to… Read More »